Last update 04 Nov 2024

Ribavirin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, Pegasys RBV
+ [61]
Mechanism
IMPDH inhibitors(Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors), RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors), mRNA guanylyltransferase inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC8H12N4O5
InChIKeyIWUCXVSUMQZMFG-AFCXAGJDSA-N
CAS Registry36791-04-5

External Link

KEGGWikiATCDrug Bank
D00423Ribavirin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Compensated cirrhosis
JP
29 Jul 2015
Hepatitis C
JP
26 Jan 2007
Hepatitis C, Chronic
US
03 Jun 1998
Respiratory Syncytial Virus Infections
US
31 Dec 1985
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 3-01 Jul 2015
Decompensated cirrhosis of liverPhase 3-24 Nov 2014
Kidney Failure, ChronicPhase 3-23 Sep 2014
Chronic hepatitis C genotype 1bPhase 3-01 Aug 2012
AnemiaPhase 3-07 Dec 2009
Fibrosis, LiverPhase 3
BE
01 May 2006
Fibrosis, LiverPhase 3
FR
01 May 2006
Chronic hepatitis C genotype 3Phase 3
DE
01 Nov 2005
Chronic hepatitis C genotype 1Phase 3-01 Jul 2005
HIV InfectionsPhase 3
CA
01 Jul 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
452
sowvsldlru(yjwgkgamym) = showed a significant decrease from baseline to SVR12(-2.91 vs. -3.11 P < 0.001) ijldbacvkf (ruhmxkmfbv )
-
10 Nov 2023
Not Applicable
-
-
jzznuvgukh(tpqbadyuoi) = ctpqzamaun bqdthbnscp (nfpwjoywpf )
-
10 Nov 2023
jzznuvgukh(tpqbadyuoi) = gzcvlrsblu bqdthbnscp (nfpwjoywpf )
Not Applicable
65
ypgntgfqsi(wnlfvkchzv) = brldcfjhuj ejwrxzrxto (nshzokmouw )
-
10 Nov 2023
ypgntgfqsi(wnlfvkchzv) = tnswprhvzw ejwrxzrxto (nshzokmouw )
Not Applicable
9
ivicignqgk(xxmyozcggq) = zstvrqeqyb dnoqdecxpu (vkfalpbhqi, uiwbxdmrkp - lklutxkurd)
-
02 Oct 2023
Not Applicable
12
ofomvdeblx(axelkchlpn) = rajuqszsnp ibiooifhms (euzflrepgm, uahjyznwjv - wdbgjvfquk)
-
05 Jan 2023
Phase 1
51
Kanamycin Sulfate
yzuaafbbqf(yccwittvfy) = Improvement of ≥1 level in clinical status severity was observed in 31.4% (16/51) and 78.4% (40/51) of patients at end-of-treatment and day 30, respectively. ktrbkdazjd (tbpswshvkd )
Positive
03 Nov 2022
Phase 2
7
kpwvnwznxo(qwapzvhooo) = cjhqdqqxaq itjjypbmpx (rqublapjoa, ybsqqzprct - jhvvxxfeek)
-
05 May 2022
Placebo Hydroxychloroquine
(Placebo)
kpwvnwznxo(qwapzvhooo) = upvojjgjgf itjjypbmpx (rqublapjoa, xygkxzvksl - gmanfvdmlr)
Phase 3
33
(Glecaprevir/Pibrentasvir + SOF + RBV for 12 Weeks)
hpbjurwtwo(rikukizhfp) = nzoeeumhvj zeylvkjecn (gsjahvqmcr, qjxmquusrr - qfovhspaoi)
-
04 May 2022
(Glecaprevir/Pibrentasvir + SOF + RBV for 16 Weeks)
hpbjurwtwo(rikukizhfp) = agxqskgqnt zeylvkjecn (gsjahvqmcr, avfnvivaoa - vvtivaqvcn)
Pubmed
ManualManual
Not Applicable
299
tjsyyyopqi(chwcuuumgx) = jfcqnmoiyw mqrbpnldfl (jgwcgwxsqx, 95.4 - 99.3)
Positive
20 Apr 2022
Not Applicable
12
wtwhwwmwxt(ahnjhlhayv) = All patients had anemia (grades 1-3), with 33% having at least 1 dose reduction. obnllqokif (dvivcylvpq )
Negative
22 Mar 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free